$19.20 Million in Sales Expected for Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) This Quarter

Equities research analysts expect Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to report sales of $19.20 million for the current quarter, according to Zacks. Five analysts have issued estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from $14.32 million to $23.00 million. The company is expected to issue its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full-year sales of $77.75 million for the current year, with estimates ranging from $59.83 million to $97.20 million. For the next fiscal year, analysts expect that the firm will post sales of $131.00 million, with estimates ranging from $93.36 million to $233.30 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Monday, May 13th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.12. The business had revenue of $12.45 million during the quarter, compared to analyst estimates of $2.40 million. During the same period in the prior year, the firm earned ($0.06) EPS.

A number of equities analysts have commented on CPRX shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Catalyst Pharmaceuticals in a report on Tuesday, March 19th. ValuEngine raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, March 25th. BidaskClub raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 27th. HC Wainwright set a $9.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, May 14th. Finally, Zacks Investment Research raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a report on Tuesday, May 21st. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $7.35.

In related news, CEO Patrick J. Mcenany bought 25,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were bought at an average cost of $3.23 per share, for a total transaction of $80,750.00. Following the completion of the purchase, the chief executive officer now owns 4,762,693 shares of the company’s stock, valued at approximately $15,383,498.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.70% of the company’s stock.

A number of hedge funds have recently bought and sold shares of CPRX. Broadfin Capital LLC lifted its stake in Catalyst Pharmaceuticals by 22.0% in the fourth quarter. Broadfin Capital LLC now owns 6,268,298 shares of the biopharmaceutical company’s stock valued at $12,035,000 after buying an additional 1,132,034 shares during the last quarter. Kennedy Capital Management Inc. bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at about $5,099,000. BlackRock Inc. raised its stake in shares of Catalyst Pharmaceuticals by 11.5% during the fourth quarter. BlackRock Inc. now owns 6,970,873 shares of the biopharmaceutical company’s stock valued at $13,384,000 after purchasing an additional 719,093 shares in the last quarter. EAM Global Investors LLC bought a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at about $1,409,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Catalyst Pharmaceuticals by 58.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 413,520 shares of the biopharmaceutical company’s stock valued at $795,000 after purchasing an additional 151,738 shares in the last quarter. Institutional investors own 59.79% of the company’s stock.

Catalyst Pharmaceuticals stock traded up $0.11 during mid-day trading on Monday, reaching $3.84. The company’s stock had a trading volume of 1,117,827 shares, compared to its average volume of 1,509,277. The company has a market capitalization of $383.65 million, a price-to-earnings ratio of -11.64 and a beta of 2.71. The firm’s 50 day moving average is $3.58. The company has a current ratio of 6.08, a quick ratio of 6.07 and a debt-to-equity ratio of 0.02. Catalyst Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $6.16.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Featured Story: What is the Rule of 72?

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.